MX2023002761A - Formulaciones de un modulador de somatostatina. - Google Patents
Formulaciones de un modulador de somatostatina.Info
- Publication number
- MX2023002761A MX2023002761A MX2023002761A MX2023002761A MX2023002761A MX 2023002761 A MX2023002761 A MX 2023002761A MX 2023002761 A MX2023002761 A MX 2023002761A MX 2023002761 A MX2023002761 A MX 2023002761A MX 2023002761 A MX2023002761 A MX 2023002761A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- tablet
- spray
- formulations
- solid dispersion
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 3
- 239000007962 solid dispersion Substances 0.000 abstract 2
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
En el presente documento se describen formulaciones de un modulador de somatostatina, los métodos de preparación de tales formulaciones y los métodos de uso de tales formulaciones en el tratamiento de afecciones, enfermedades o trastornos que podrían beneficiarse de la modulación de la actividad de la somatostatina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063076024P | 2020-09-09 | 2020-09-09 | |
PCT/US2021/049282 WO2022055880A1 (en) | 2020-09-09 | 2021-09-07 | Formulations of a somatostatin modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002761A true MX2023002761A (es) | 2023-04-03 |
Family
ID=78078387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002761A MX2023002761A (es) | 2020-09-09 | 2021-09-07 | Formulaciones de un modulador de somatostatina. |
Country Status (14)
Country | Link |
---|---|
US (2) | US11266641B1 (es) |
EP (1) | EP4210700A1 (es) |
JP (1) | JP2023540137A (es) |
KR (1) | KR20230066379A (es) |
CN (1) | CN116456968A (es) |
AR (1) | AR123453A1 (es) |
AU (1) | AU2021341936A1 (es) |
CA (1) | CA3191084A1 (es) |
CL (1) | CL2023000627A1 (es) |
CO (1) | CO2023004346A2 (es) |
IL (1) | IL301038A (es) |
MX (1) | MX2023002761A (es) |
TW (1) | TW202227072A (es) |
WO (1) | WO2022055880A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102324042B1 (ko) | 2016-07-14 | 2021-11-09 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 및 그의 용도 |
CN116456968A (zh) | 2020-09-09 | 2023-07-18 | 克林提克斯医药股份有限公司 | 生长抑素调节剂的制剂 |
TW202339747A (zh) * | 2022-01-11 | 2023-10-16 | 美商克林提克斯醫藥股份有限公司 | 生長抑制素調節劑用於治療類癌症候群(carcinoid syndrome)之用途 |
CN115919866A (zh) * | 2022-12-07 | 2023-04-07 | 深圳海王医药科技研究院有限公司 | 特泊替尼固体分散体及其制备方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
JP2005518365A (ja) | 2001-11-27 | 2005-06-23 | メルク エンド カムパニー インコーポレーテッド | 4−アミノキノリン化合物 |
JP4216196B2 (ja) | 2002-02-04 | 2009-01-28 | エフ.ホフマン−ラ ロシュ アーゲー | Npyアンタゴニストとしてのキノリン誘導体 |
US7767817B2 (en) | 2003-09-05 | 2010-08-03 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
WO2006017326A1 (en) | 2004-07-13 | 2006-02-16 | Glaxo Group Limited | Antibacterial agents |
US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
PL1959948T3 (pl) | 2005-12-05 | 2012-12-31 | Xenoport Inc | Metanosulfonian proleku lewodopy, jego kompozycje, oraz jego zastosowania |
JP2009527562A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体 |
JP2009529060A (ja) | 2006-03-08 | 2009-08-13 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのキノリン及びイソキノリン誘導体 |
US20090258853A1 (en) | 2006-03-13 | 2009-10-15 | Brian Eastman | Somatostatin Agonists |
US8871728B2 (en) | 2007-06-29 | 2014-10-28 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof |
EP2342190A1 (en) | 2008-09-02 | 2011-07-13 | Novartis AG | Bicyclic kinase inhibitors |
GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
MX342879B (es) | 2010-07-30 | 2016-10-14 | Oncotherapy Science Inc * | Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
EP2726465A1 (en) | 2011-05-23 | 2014-05-07 | Elan Pharmaceuticals Inc. | Inhibitors of lrrk2 kinase activity |
US9281726B2 (en) | 2011-05-31 | 2016-03-08 | Linak A/S | Actuator |
US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
DE102011113749A1 (de) | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
US20140228417A1 (en) | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
JP2015524457A (ja) | 2012-08-06 | 2015-08-24 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | ジヒドロキシピリミジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防における使用 |
MX2015004784A (es) | 2012-10-16 | 2015-08-14 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t. |
CA2921427A1 (en) | 2013-08-16 | 2015-02-19 | Duke University | Substituted hydroxamic acid compounds |
JP6380402B2 (ja) | 2013-09-30 | 2018-08-29 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
CA2943643A1 (en) | 2014-03-24 | 2015-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
US20160193285A1 (en) | 2014-12-10 | 2016-07-07 | Chiasma Inc. | Oral octreotide administered in combination with other therapeutic agents |
WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
US9902703B2 (en) | 2015-07-01 | 2018-02-27 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
SG11201803408PA (en) * | 2015-10-30 | 2018-05-30 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
EP3374350B1 (en) | 2015-11-09 | 2022-01-05 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
SG11201804170RA (en) | 2015-12-17 | 2018-06-28 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
JP6870082B2 (ja) | 2016-07-07 | 2021-05-12 | プランテックス・リミテッド | 二メシル酸パルボシクリブの固体形態 |
KR102324042B1 (ko) | 2016-07-14 | 2021-11-09 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 및 그의 용도 |
JP7106564B2 (ja) | 2017-03-16 | 2022-07-26 | クリネティックス ファーマシューティカルズ,インク. | ソマトスタチンモジュレータとその使用 |
EP3621961A4 (en) | 2017-05-10 | 2020-09-09 | Forge Therapeutics, Inc. | ANTIBACTERIAL COMPOUNDS |
WO2019030302A1 (en) * | 2017-08-11 | 2019-02-14 | Merck Patent Gmbh | PHARMACEUTICAL PREPARATION COMPRISING 3-FLUORO-4- [7-METHOXY-3-METHYL-8- (1-METHYL-1H-PYRAZOL-4-YL) -2-OXO -2,3-DIHYDRO-IMIDAZO [4,5] -C] QUINOLIN-1-YL] -BENZONITRILE |
HRP20220852T1 (hr) | 2018-01-17 | 2022-10-14 | Crinetics Pharmaceuticals, Inc. | Postupak za izradu modulatora somatostatina |
EP3853218A4 (en) | 2018-09-18 | 2022-02-16 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND USES THEREOF |
EP3999509A4 (en) | 2019-07-17 | 2023-07-19 | Crinetics Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS |
CN116456968A (zh) | 2020-09-09 | 2023-07-18 | 克林提克斯医药股份有限公司 | 生长抑素调节剂的制剂 |
BR112023024465A2 (pt) | 2021-05-25 | 2024-02-06 | Crinetics Pharmaceuticals Inc | Usos de um modulador de somatostatina para o tratamento de doença |
-
2021
- 2021-09-07 CN CN202180068588.2A patent/CN116456968A/zh active Pending
- 2021-09-07 US US17/468,440 patent/US11266641B1/en active Active
- 2021-09-07 KR KR1020237011002A patent/KR20230066379A/ko unknown
- 2021-09-07 AU AU2021341936A patent/AU2021341936A1/en active Pending
- 2021-09-07 IL IL301038A patent/IL301038A/en unknown
- 2021-09-07 CA CA3191084A patent/CA3191084A1/en active Pending
- 2021-09-07 JP JP2023515559A patent/JP2023540137A/ja active Pending
- 2021-09-07 WO PCT/US2021/049282 patent/WO2022055880A1/en active Application Filing
- 2021-09-07 MX MX2023002761A patent/MX2023002761A/es unknown
- 2021-09-07 EP EP21786673.0A patent/EP4210700A1/en active Pending
- 2021-09-08 AR ARP210102492A patent/AR123453A1/es unknown
- 2021-09-08 TW TW110133308A patent/TW202227072A/zh unknown
-
2022
- 2022-01-25 US US17/584,225 patent/US11957674B2/en active Active
-
2023
- 2023-03-03 CL CL2023000627A patent/CL2023000627A1/es unknown
- 2023-04-04 CO CONC2023/0004346A patent/CO2023004346A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021341936A1 (en) | 2023-05-25 |
US11957674B2 (en) | 2024-04-16 |
US20220143007A1 (en) | 2022-05-12 |
WO2022055880A1 (en) | 2022-03-17 |
IL301038A (en) | 2023-05-01 |
CA3191084A1 (en) | 2022-03-17 |
US11266641B1 (en) | 2022-03-08 |
TW202227072A (zh) | 2022-07-16 |
EP4210700A1 (en) | 2023-07-19 |
AR123453A1 (es) | 2022-11-30 |
JP2023540137A (ja) | 2023-09-21 |
CO2023004346A2 (es) | 2023-04-27 |
CN116456968A (zh) | 2023-07-18 |
CL2023000627A1 (es) | 2023-09-01 |
US20220071986A1 (en) | 2022-03-10 |
KR20230066379A (ko) | 2023-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002761A (es) | Formulaciones de un modulador de somatostatina. | |
US20220016059A1 (en) | Methods for the treatment of bladder cancer | |
US12011449B2 (en) | Therapeutic combinations comprising a c-RAF inhibitor | |
NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
EP3219308A1 (en) | Melt-extruded solid dispersions containing an apoptosis-inducing agent | |
WO2002092088A3 (en) | Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts | |
Protopopova et al. | In search of new cures for tuberculosis | |
WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
JP2019506387A5 (es) | ||
US20230233530A1 (en) | Implantable isoxazoline pharmaceutical compositions and uses thereof | |
EP4306113A3 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
MX2023009833A (es) | Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. | |
JP2022553313A (ja) | セレキシパグを含む医薬組成物 | |
JP2006508933A (ja) | エンドセリン受容体拮抗薬の投与に起因する頭痛の治療のための5−ht1b/1d受容体作動薬 | |
JP7190891B2 (ja) | ダサチニブを有効成分とする医薬錠剤及びその製造方法 | |
WO2016075617A1 (en) | Fixed dose pharmaceutical formulations of analgesic and anti-spasmodic drugs | |
Cornelison et al. | Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation | |
KR102640532B1 (ko) | 신규한 테비페넴 피복실 속방형 및 변형 방출형 경구 투여형 | |
WO2005058341A3 (en) | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases | |
JP7189327B2 (ja) | ヘリコバクターピロリ菌を除菌するための組成物 | |
ZA202306190B (en) | Amorphous solid dispersion formulation | |
US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
WO2004037228A1 (en) | Sustained release compositions containing alfuzosin | |
JP2021503448A5 (es) | ||
ZA202200331B (en) | Naltrexone formulation |